This study is a Phase 1 randomized, double-blind, placebo-controlled, single, and multiple ascending dose study in HV with food effect cohort, and a repeat dose expansion cohort(s) in participants with ALS.~The study consists of 3 parts, as follows:~Part 1: SAD in HV with up to 6 cohorts including a food effect cohort.~Part 2: MAD over 5 days in HV with up to 5 cohorts~Part 3: ALS cohorts with once daily (QD) dosing over 28 days
The first-in-human Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SPG302 in healthy volunteers and ALS participants